![ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment | UEG - United European Gastroenterology ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment | UEG - United European Gastroenterology](https://my.ueg.eu/library/societies/30f27278-9293-11ed-b860-0242ac140004.jpg)
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment | UEG - United European Gastroenterology
![Stopping infliximab but not antimetabolites leads to more relapses in Crohn's disease - Medical Conferences Stopping infliximab but not antimetabolites leads to more relapses in Crohn's disease - Medical Conferences](https://conferences.medicom-publishers.com/wp-content/uploads/2022/04/ECCO2022_Figure-Relapse-rate-over-time.png)
Stopping infliximab but not antimetabolites leads to more relapses in Crohn's disease - Medical Conferences
![ECCO update on COVID-19 and IBD | International Organization For the Study of Inflammatory Bowel Disease ECCO update on COVID-19 and IBD | International Organization For the Study of Inflammatory Bowel Disease](https://ioibd.org/wp-content/uploads/2020/04/news-ecco-1080x675.jpg)
ECCO update on COVID-19 and IBD | International Organization For the Study of Inflammatory Bowel Disease
![Peter Bossuyt, ECCO-IBD 2022: Risankizumab in Crohn's Disease - Post Hoc Analysis of ADVANCE, MOTIVATE, and FORTIFY - touchIMMUNOLOGY Peter Bossuyt, ECCO-IBD 2022: Risankizumab in Crohn's Disease - Post Hoc Analysis of ADVANCE, MOTIVATE, and FORTIFY - touchIMMUNOLOGY](https://embed-ssl.wistia.com/deliveries/609958c243bd916768548d33987b8700.webp?image_crop_resized=960x540)
Peter Bossuyt, ECCO-IBD 2022: Risankizumab in Crohn's Disease - Post Hoc Analysis of ADVANCE, MOTIVATE, and FORTIFY - touchIMMUNOLOGY
![Table 2 from Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. | Semantic Scholar Table 2 from Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. | Semantic Scholar](https://ai2-s2-public.s3.amazonaws.com/figures/2017-08-08/9177b4ea36dc064d0157292a81e7740800f0890a/20-Figure2-1.png)
Table 2 from Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. | Semantic Scholar
![Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel | Gut Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel | Gut](https://gut.bmj.com/content/gutjnl/70/6/1044/F1.large.jpg)
Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel | Gut
![Fernando Magro, CINTESIS Researcher, Elected President of the ECCO - European Crohn's and Colitis Organisation - CINTESIS Fernando Magro, CINTESIS Researcher, Elected President of the ECCO - European Crohn's and Colitis Organisation - CINTESIS](https://cintesis.eu/wp-content/uploads/sites/755/2023/03/Foto-magro-cintesis.jpg)